"Sunil, a seasoned pharmaceutical executive, is a welcome addition to the Calithera Board of Directors as we advance our pipeline through clinical development," said
Dr. Agarwal commented, "I am honored to join Calithera's Board of Directors at this exciting time as they advance their novel, first in class, tumor metabolism and immuno-oncology anti-cancer agents."
Dr. Agarwal is currently Senior Vice President and Chief Medical Officer at Ultragenyx where he is responsible for leading the company's clinical development. Prior to Ultragenyx, Dr. Agarwal served in various leadership capacities at Genentech for 11 years. Most recently he held the position of Senior Vice President and Global Head of Clinical Development for
Forward Looking Statements
This news release contains forward-looking statements by Calithera regarding the advancement of Calithera's product candidates through clinical development. These forward-looking statements involve risks and uncertainties. Actual results may differ from Calithera's expectations and important factors that could cause actual results to differ materially. Calithera's product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the
Jennifer McNealeyir@Calithera.com 650-870-1071